Suivre
Abonner Eisai Europe Limited

Eisai Europe Limited

Filtre
  • 09.05.2013 – 14:23

    First Clinical Experiences With Fycompa® (perampanel) Show "Clear Therapeutic Benefit"

    Hatfield, England (ots/PRNewswire) - New data on early real life experience show perampanel is effective and well tolerated in patients with difficult-to-treat partial epilepsy The antiepileptic drug (AED) Fycompa (perampanel), shows a clear therapeutic benefit in difficult-to-treat patients with partial epilepsy according to the investigators of two new analyses on ...

  • 02.04.2013 – 06:02

    Inovelon®(rufinamide) Oral Suspension Formulation Launched in France

    Hatfield, England (ots/PRNewswire) - Child friendly formulation will help treatment of orphan syndrome LGS a severe form of childhood epilepsy Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in France. The new formulation of the orphan ...

  • 07.01.2013 – 01:02

    New First-in-class Treatment Fycompa® Launches in Norway for Most Common Form of Epilepsy

    Hatfield, England (ots/PRNewswire) - Eisai today launches Fycompa(R) (perampanel) in Norway as a treatment for partial-onset seizures, with or without secondarily generalised seizures, in people with epilepsy aged 12 years and older.[1] Perampanel is the first in an entirely new class of treatment for uncontrolled partial epilepsy, the most common form of the ...

  • 02.01.2013 – 07:01

    Inovelon® (rufinamide) Oral Suspension Formulation Launched in Spain

    Hatfield, England (ots/PRNewswire) - Child friendly formulation set to aid administration for the treatment of Lennox-Gastaut syndrome Inovelon(R) (rufinamide) oral suspension for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in children four years and older is launched today in Spain. As many patients who receive the orphan ...

  • 10.07.2012 – 01:35

    Eisai Expands in Israeli Market With Approval of Halaven

    Hatfield, England (ots/PRNewswire) - Metastatic breast cancer treatment Halaven(R) (eribulin) provides a statistically significant overall survival benefit for women with the disease Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has recently received registration approval from ...

  • 10.07.2012 – 01:34

    New Breast Cancer Treatment Available in France

    Hatfield, England (ots/PRNewswire) - Reimbursement granted for Halaven(R) (eribulin) for women with locally advanced or metastatic breast cancer Halaven(R) (eribulin), a novel treatment for patients with locally advanced or metastatic breast cancer who have progressed after at least two chemotherapeutic regimens for advanced disease, has today received reimbursement approval from the French health authorities. Prior ...

  • 27.06.2012 – 01:03

    Eisai Enters Russian Market With Approval of First Product

    Hatfield, England (ots/PRNewswire) - Zonegran(R) (zonisamide) set to offer new option for epilepsy treatment in Russia Eisai, one of the world's leading research-based pharmaceutical companies, announces the expansion of its operations into Russia, with the approval of its first product - the epilepsy treatment, Zonegran(R) (zonisamide). Eisai's entry into the Russian healthcare marketplace is part of the company's plan ...

  • 23.05.2012 – 10:31

    Once-Daily Epilepsy Treatment now Available in Sweden

    Hatfield, England (ots/PRNewswire) - ? Reimbursement granted for Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited today announces the launch of Zebinix(R) (eslicarbazepine acetate) which will receive full reimbursement from the Swedish health authorities. Once-daily Zebinix is indicated as an adjunctive (add-on) therapy for adults with partial-onset ...

  • 18.05.2012 – 01:03

    Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting

    Hatfield, England (ots/PRNewswire) - Eisai announced today that 12 abstracts highlighting new study results will be presented during the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO), taking place in Chicago, USA, from 1-5 June 2012. These studies highlight Eisai's current product portfolio and oncology pipeline, reinforcing the company's ...

  • 18.04.2012 – 01:05

    Novel Once-Daily Epilepsy Treatment now Available in France

    Hatfield, England (ots/PRNewswire) - Reimbursement granted for Zebinix(R) as adjunctive therapy for adults with partial-onset seizures Eisai Europe Limited announces the launch of Zebinix(R) (eslicarbazepine acetate) in France. Upon launch, this novel epilepsy drug will receive full reimbursements from the French health authorities. Once-daily eslicarbazepine acetate is indicated as an adjunctive (add-on) therapy for ...

  • 18.04.2012 – 01:03

    Eisai Opens Representative Office in Dubai

    Hatfield, England (ots/PRNewswire) - New EMEA Dubai Office Part of Expansion Plans into Middle East and Parts of Africa PRESS RELEASE NOT INTENDED FOR DUBAI MEDIA Japanese company Eisai is expanding its geographical and patient reach by opening a new regional representative office in Dubai today. The Eisai EMEA (Europe, Middle East and Africa) Dubai branch office, located in Dubai Healthcare City (DHCC), marks the ...

  • 17.04.2012 – 01:03

    Inovelon® (rufinamide) Drinkable Suspension Launches in Denmark

    Hatfield, England (ots/PRNewswire) - Child-friendly formulation now available for the treatment of Lennox-Gastaut syndrome Eisai Europe Limited today announced the launch of Inovelon(R) (rufinamide) oral suspension in Denmark for adjunctive (add-on) treatment of seizures associated with Lennox-Gastaut syndrome (LGS), in children four years and older. Many patients who receive the orphan drug rufinamide are children, ...

  • 10.02.2011 – 01:03

    Zebinix, Novel Once-Daily Anti-Epileptic Treatment, Launches in Spain

    Hatfield, England (ots/PRNewswire) - Zebinix(R) (eslicarbazepine acetate), an add-on (adjunctive) therapy for adults with partial-onset seizures, with or without secondary generalisation (where the seizure spreads to both sides of the brain), has been launched today in Spain by Eisai and BIAL in a co-promotion. In 2009, the European Commission approved Zebinix ...

  • 13.01.2011 – 14:24

    Eisai Opens for Business in the Netherlands

    Hatfield, England (ots/PRNewswire) - Eisai Europe Limited, a subsidiary of Eisai Co., Ltd announces the establishment of its sales and marketing operation in its wholly owned subsidiary in the Netherlands based in Amsterdam. The first Eisai product on the Dutch market is the epilepsy treatment Zonegran (zonisamide). Commenting on the opening of the new subsidiary, Eisai Netherlands Managing Director, Mr Gert-Jan ...

  • 26.06.2009 – 13:36

    Eisai Opens GBP100 Million European Headquarters Facility in the UK

    Hatfield, England (ots/PRNewswire) - - Leading Research-Based Pharmaceutical Company Creates New Manufacturing and Research Jobs in UK Eisai, one of the world's leading pharmaceutical companies, today officially opened its new 'European Knowledge Centre' (the EKC) in Hatfield, Hertfordshire. Committed to developing new medicines for patients ...